ARQT - Arcutis initiaties Phase 3 clinical trials of topical roflumilast cream

Arcutis Biotherapeutics (ARQT) has commenced pivotal Phase 3 clinical trials evaluating topical roflumilast cream ARQ-151 as a potential treatment for atopic dermatitis.“More than 19M people in the U.S. suffer from atopic dermatitis, of which at least 60% are young children, thereby making safety and tolerability particularly important in this disease,” said Patrick Burnett, M.D., Ph.D., FAAD, Arcutis’ Chief Medical Officer.The Co. believe topical roflumilast has the potential to eliminate the need to compromise between safety, efficacy, and tolerability, and look forward to reporting topline data in the 2H 2022. In each trial, ~650 subjects are planned to be randomized 2:1 to either roflumilast cream 0.15% or matching vehicle cream.

For further details see:

Arcutis initiaties Phase 3 clinical trials of topical roflumilast cream